Eti Meiri - Rosetta Genomics Vice President - Research
President
Dr. Eti Meiri serves as Vice President Research of the company. She previously served as our Senior Scientist, Molecular Biology since 2003. She was contributing to our science and was extremely instrumental in all of the RD activities throughout the years. Her contributions included the development of our microRNA array platform as well as the development of RNA extraction protocols suitable for microRNA extraction from clinical samples. Prior to joining us, from 2001 to 2002, Dr. Meiri served as Senior Scientist in ViroGene Ltd. She is the author of 20 papers published in peer reviewed journals
| Age | 45 |
| Professional Marks | Ph.D |
| Phone | 972 73 222 0700 |
| Web | http://www.rosettagx.com |
Rosetta Genomics Management Efficiency
The company has return on total asset (ROA) of (60.19) % which means that it has lost $60.19 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (137.95) %, meaning that it created substantial loss on money invested by shareholders. Rosetta Genomics' management efficiency ratios could be used to measure how well Rosetta Genomics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.45 M in liabilities with Debt to Equity (D/E) ratio of 222.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Rosetta Genomics has a current ratio of 2.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Rosetta Genomics until it has trouble settling it off, either with new capital or with free cash flow. So, Rosetta Genomics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rosetta Genomics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rosetta to invest in growth at high rates of return. When we think about Rosetta Genomics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Jerome Grant | Universal Technical Institute | 61 | |
| Tim Bozik | Pearson PLC ADR | 62 | |
| Rod Bristow | Pearson PLC ADR | 62 | |
| Roger Sherrard | Parker Hannifin | 54 | |
| David Chung | 51Talk Online Education | N/A | |
| Ting Shu | 51Talk Online Education | 38 | |
| Joseph Leonti | Parker Hannifin | 52 | |
| Todd Leombruno | Parker Hannifin | 54 | |
| Michael Murray | DR Horton | 58 | |
| Michael Wee | Parker Hannifin | N/A | |
| Kevin Capitani | Pearson PLC ADR | N/A | |
| Rob Malone | Parker Hannifin | 51 | |
| Robert Whelan | Pearson PLC ADR | 75 | |
| Jennifer Parmentier | Parker Hannifin | 57 | |
| Paul Romanowski | DR Horton | 53 | |
| Bill Wheat | DR Horton | 58 | |
| Robert Malone | Parker Hannifin | 57 | |
| Troy Anderson | Universal Technical Institute | 56 | |
| Catherine Suever | Parker Hannifin | 60 | |
| Andrew Weeks | Parker Hannifin | 57 | |
| Piper Jameson | Universal Technical Institute | 53 | |
Management Performance
| Return On Equity | -137.95 | |||
| Return On Asset | -60.19 |
Rosetta Genomics Leadership Team
Elected by the shareholders, the Rosetta Genomics' board of directors comprises two types of representatives: Rosetta Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rosetta. The board's role is to monitor Rosetta Genomics' management team and ensure that shareholders' interests are well served. Rosetta Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rosetta Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Sidransky, Independent Director | ||
| Kenneth Berlin, CEO and Pres | ||
| Anne Fields, IR Contact Officer | ||
| Joshua Rosensweig, Director | ||
| Dganit Bar, Chief Scientific Officer | ||
| Brian Markison, Chairman, Observer To Board of Directors and Member of Nominating and Corporate Governance Committee | ||
| Douglas Sites, Executive Vice President - Sales and Marketing | ||
| Tal YaronEldar, Independent Director | ||
| Eti Meiri, Vice President - Research | ||
| Robert Wassman, Chief Medical Officer | ||
| Oded Biran, General Counsel | ||
| Roy Davis, Director | ||
| Yitzhak Peterburg, Director | ||
| Kevin Watson, Director, Reimbursement-Managed Care | ||
| Ron Kalfus, CFO | ||
| Gerald Dogon, External Independent Director | ||
| Tali YaronEldar, External Independent Director |
Rosetta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rosetta Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -137.95 | |||
| Return On Asset | -60.19 | |||
| Operating Margin | (370.55) % | |||
| Current Valuation | 2.09 M | |||
| Shares Outstanding | 5.93 M | |||
| Shares Owned By Insiders | 0.20 % | |||
| Shares Owned By Institutions | 14.42 % | |||
| Number Of Shares Shorted | 310.26 K | |||
| Price To Earning | (0.09) X | |||
| Price To Book | 1.01 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Rosetta Genomics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Rosetta Genomics' short interest history, or implied volatility extrapolated from Rosetta Genomics options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Rosetta Stock
If you are still planning to invest in Rosetta Genomics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rosetta Genomics' history and understand the potential risks before investing.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |